Target Information
Target General Infomation | |||||
---|---|---|---|---|---|
Target ID |
T70888
|
||||
Target Name |
TNF receptor
|
||||
Target Type |
Clinical Trial
|
||||
Disease | Asthma [ICD10: J45] | ||||
Human immunodeficiency virus infection [ICD9: 279.3; ICD10: B20-B26] | |||||
Inflammatory disorder [ICD code not available] | |||||
Pemphigus vulgaris; Vasculitis; Wegener's granulomatosis [ICD10: C91-C95, J45, J84.1, L80, M081, M45, M35.0, M40-M54, T86.0] | |||||
Sciatica [ICD10: M54.3-M54.4] | |||||
BioChemical Class |
Tumor necrosis factor receptor superfamily (TNFRSF)
|
||||
Drugs and Mode of Action | |||||
Drug(s) | Etanercept | Drug Info | Approved | Active rheumatoid arthritis | [556264] |
Etanercept | Drug Info | Phase 3 | Sciatica | [526617], [541869] | |
Etanercept | Drug Info | Phase 2 | Pemphigus vulgaris; Vasculitis; Wegener's granulomatosis | [889316], [889317], [889318], [889319], [889323], [889324], [889328], [889329], [889330], [889331], [889332], [889333], [889334], [889346], [889362], [889363], [889384], [889419] | |
TgAAV-TNFR:Fc | Drug Info | Phase 1/2 | Inflammatory disorder | [527270] | |
Lenercept | Drug Info | Discontinued in Phase 3 | Asthma | [545793] | |
BB-2275 | Drug Info | Terminated | Human immunodeficiency virus infection | [545434] | |
References | |||||
Ref 526617 | Etanercept, a TNF antagonist for treatment for psoriatic arthritis and psoriasis. Skin Therapy Lett. 2003 Jan;8(1):1-4. | ||||
Ref 527270 | Secretion of a TNFR:Fc fusion protein following pulmonary administration of pseudotyped adeno-associated virus vectors. J Virol. 2004 Nov;78(22):12355-65. | ||||
Ref 541869 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6789). | ||||
Ref 545434 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003251) | ||||
Ref 545793 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004745) | ||||
Ref 889319 | ClinicalTrials.gov (NCT00006070) Etanercept (Enbrel) to Treat Pain and Swelling After Third Molar Extraction | ||||
Ref 889323 | ClinicalTrials.gov (NCT00034060) The Role of Cytokines on Growth Hormone Suppression in Premenopausal Women With Rheumatoid Arthritis and the Effect of Treatment With Etanercept | ||||
Ref 889324 | ClinicalTrials.gov (NCT00063869) Study Evaluating the Safety and Efficacy of Etanercept in Patients With Idiopathic Pulmonary Fibrosis | ||||
Ref 889329 | ClinicalTrials.gov (NCT00134368) Study of the Efficacy and Safety of Etanercept in Adults With Vitiligo | ||||
Ref 889330 | ClinicalTrials.gov (NCT00135720) Study of Etanercept (Enbrel) in the Treatment of Pemphigus Vulgaris | ||||
Ref 889331 | ClinicalTrials.gov (NCT00141713) The Use of Etanercept (Enbrel) in the Treatment of Acute Graft-Versus-Host Disease | ||||
Ref 889332 | ClinicalTrials.gov (NCT00141726) Study of Enbrel (Etanercept) for the Treatment Sub-Acute Pulmonary Dysfunction After Allogeneic Stem Cell Transplant | ||||
Ref 889333 | ClinicalTrials.gov (NCT00141739) Study of Etanercept for the Prevention of Complications Resulting From Hematopoietic Stem Cell Transplantation (HSCT) | ||||
Ref 889362 | ClinicalTrials.gov (NCT01289730) Etanercept (Enbrel) in Undifferentiated Spondyloarthritis |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.